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Cell transplantation has been proposed to replace lost neurons in the diseased brain, and after
injuries to the central nervous system (CNS). Strategies for cellular therapy in the CNS consist
primarily in heterologous transplantations. Despite the CNS being an immunologically privileged
site, immune rejection of intracerebral transplants remains a concern. In addition, the use of
immunosuppressive drugs, like cyclosporine, is a major constraint associated with heterologous
transplantations. Autologous transplantation is therefore viewed as the model of choice for cellular
therapy. With the recent progress in somatic cell nuclear transfer (SCNT) research, and the
confirmation that neurogenesis occurs in the adult brain and neural stem cells (NSCs) reside in the
adult CNS, new opportunities for autologous transplantations are being considered for the CNS,
and are promising.
Key words Adult neurogenesis - cellular therapy - embryonic stem cells - olfactory ensheating cells - neural stem cells -
plasticity - somatic cell nuclear transfer
Review Article
Indian J Med Res 124, December 2006, pp 613-618
The central nervous system (CNS) is an
immunologically privileged site, where grafts survive
longer than in other organs and tissues1. Therefore,
allogeneic and xenogeneic transplantations are
candidate strategies to replace lost neurons in
neurodegenerative diseases, and after injuries to the
CNS. Cell types from various sources have been
considered and evaluated for therapy in the CNS, and
have shown promising results in preclinical studies,
and clinical trials2. Despite the CNS being an
immunologically privileged site, immune rejection of
intracerebral transplants remains a concern. On the
one hand, genetically matching the donor-recipient and
the use of immunosuppressive drugs to avoid tissue
rejection are major constraints to allogeneic
transplantations. Finding a matching donor represents
a challenge, and immunosuppressive treatments, like
cyclosporine, are not very well tolerated by patients,
and may also compromise the effectiveness of the
transplanted cells3. On the other hand, encapsulation
of xenogeneic cell lines has been suggested as a way
to avoid immune responses. However, there are
examples of immune response against encapsulated
cells resulting in graft destruction. Further, the
possibility of transmittable xenozoonoses, the host
long-term response to xenograft and the ethical issues
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over grafting of non human tissues into the human
CNS, are major limitations to xenotransplantation4.
In fact, it is now clear that the CNS does not display
absolute immunological privilege, and that the
immune response of the CNS to grafted tissue depends
on a number of variables, which include the
phylogenic relationship of donor to the host, its
composition, mode and site of implantation3. In
addition, in the context of neural grafting, there will
be inevitable damage to the blood-brain barrier (BBB),
further weakening the immune protection of the CNS.
Altogether, these data support autologous
transplantation as a model of choice for cellular
therapy in the CNS. Autologous transplantation
obviates the need of donor-recipient matching and the
use of immune-suppressive drugs, conditions that
would favour successful graft integration, survival and
recovery. In this review, we will discuss about the
various cell types considered, and evaluated for
autologous transplantation in the CNS.
Lineage fated cells
Chromaffin cells and sympathetic neurons: Cells
from the sympathoadrenal (SA) lineage, chromaffin
cells - the neuroendocrine cells of the adrenal
medulla - and sympathetic neurons, mostly release
noradrenaline, though some of them produce and
release dopamine5. Parkinson’s disease (PD) is a
chronic and progressive neurodegenerative disease
primarily associated with the loss of dopaminergic
neurons in the substantia nigra. SA cells also express
dopaminotrophic factors, like glial-derived
neurotrophic factor (GDNF) and transforming growth
factor-b, which protect dopaminergic neurons from
degeneration. Hence, SA cells have been proposed
for the treatment of PD. Chromaffin cells and
sympathetic neurons have been transplanted, either
freshly isolated or after expansion in culture, into
the denervated striatum and reported to exert
beneficial effects in animal models of PD, and in
clinical trials5. Since the proportion of dopaminergic
cells in SA tissue transplanted is very low i.e., only
1 per cent of the entire adrenal chromaffin cell
population releases dopamine, the beneficial activity
of transplanted adrenal cells on PD symptoms may
results from its neurotrophic effect, rather than from
the release of dopamine. One of the advantages of
SA transplantation is the ability to isolate cells from
the patients, allowing autologous transplantations.
However, the survival of adrenal medulla grafts,
either chromaffin cells or sympathetic neurons, is low
in animal models of PD and extremely low after
grafting in PD patients. Hence, despite the ability to
isolate and purified adrenal cells in extremely high
quantities and to perform autologous transplantation,
this approach is no longer pursued clinically.
Fibroblasts: Fibroblasts can be easily isolated from
individuals and grown in vitro, providing a source
of tissue for autologous transplantation. To take
advantage of these properties for the treatment of
CNS diseases and injuries, fibroblasts have been
genetically engineered, to express trophic factors or
to produce neurotransmitter-synthesizing enzymes6.
Pre-clinical studies reveal that fibroblasts genetically
engineered to express brain-derived neurotrophic
factor or acetylcholine promote neuronal survival,
regeneration, and functional recovery in animal
models of CNS diseases and injuries7,8. Recently,
fibroblasts genetically engineered to express nerve
growth factor, transplanted in patients with
Alzheimer’s disease, have been shown to improve
the patients’ abilities to recover9, validating such
strategy for cellular therapy. However, the main
concerns over the use of genetically engineered cells,
and particularly fibroblasts, for cellular therapy
reside over the long-term expression of the transgene,
and the need to develop vectors allowing sustained
expression of the transgene10.
Olfactory ensheating cells: Olfactory ensheathing
cells (OECs) are a specialized population of glial
cells that ensheath olfactory axons in the olfactory
bulb (OB), the region of termination of the olfactory
sensory axons in the CNS, and the olfactory mucosa,
the olfactory epithelium of the nasal cavity11. OECs
have unique properties. They reside both inside and
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outside the CNS. They are non-myelinating glial cells
that play a role in guiding the axons as they grow
from the olfactory mucosa through the lamina propria
to the OB. OECs have therefore properties of both
astrocytes and Schwann cells, in being able to live
within the CNS and in assisting axonal growth,
respectively. Because of their properties to support
axonal growth, OECs have been proposed for cellular
therapy in the nervous system, particularly for spinal
cord injuries12-15. Preclinical studies reveal that when
transplanted into the spinal cord after injury, like after
corticospinal tract lesions, OECs are associated with
myelinating regrowing axons and functional
improvements in locomotor abilities. These results
have been reported for OECs from the OB, but also
from the nose16. As OECs of the olfactory mucosa
can be obtained by simple biopsy from the nose in
all individuals without affecting the sense of smell
and grown in vitro, OECs represent a potential
candidate for autologous transplantation in the
nervous system, particularly for spinal cord repair17.
Human OECs have been reported to remyelinate
spinal cord injuries in rodent after transplantation,
and are being evaluated in phase I clinical trial, in
which autologous OECs are transplanted in the
injured spinal cord of paraplegic humans18.
Genetically engineered OECs to produce growth
factors, like GDNF, promote survival and
regenerative mechanisms within the host tissue,
further supporting the potential of OECs for cellular
therapy15. Altogether, these results show that OECs
represent a promising strategy for cellular therapy
by autologous transplantation in the nervous system,
particularly for spinal cord injury.
Stem cells
Embryonic stem cells: Embryonic stem cells (ESCs)
are the self-renewing pluripotent cells derived from
the inner cell mass of blastocysts. ESCs have the
potential to generate all the lineages of the individual.
As such, ESCs hold the promise to cure a broad range
of diseases and injuries, particularly of the CNS19.
With the advances in somatic cell nuclear transfer
(SCNT), there is the potential to generate isogeneic
ESCs, carrying a set of chromosomes identical to that
of an individual. SCNT consists in isolating nucleus
of a somatic cell type, like fibroblast, from an
individual and transfer it into an enucleated oocyte
from a female donor. By mechanisms still unknown,
the cytoplasm of the oocyte reprogrammes the
chromosomes of the somatic cell’s nucleus, and the
cloned cells develop into a blastocyst from which
ESCs can be derived20. Isogeneic ESCs, carrying the
genetic make-up of the individual, are therefore
unlikely to be rejected after transplantation back into
the individual. SCNT has been successfully applied
to clone various animals, and to derive ESCs from
various species, supporting SCNT has a valid strategy
for generating isogeneic ECS lines for
transplantation21. However, ethical issues over the
destruction of human blastocysts remain a major
limitation for the therapeutic application of SCNT.
Further, the generation of isogeneic ESCs by SCNT
from human remains to be established22.
Adult neural stem cells: Neural stem cells (NSCs)
are the self-renewing multipotent cells that generate
the main cell types of the nervous system, neurons,
astrocytes and oligodendrocytes. NSCs hold the
promise to treat a broad range of CNS diseases and
injuries. The recent confirmation that neurogenesis
occurs in the adult brain and NSCs reside in the adult
CNS in mammals, including human, provides new
alternatives for cellular therapy23. Self-renewing
multipotent NSCs have been isolated and
characterized from various areas of the adult CNS
including the spinal cord, and from various species,
including from human (biopsies and post-mortem
tissues). Adult-derived neural progenitor and stem
cells have been transplanted in animal models, and
shown functional engraftment, supporting their
potential use for therapy23. The ability to isolate and
culture neural progenitor and stem cells from adult
tissue open the opportunity to perform autologous
transplantation, in which neural progenitor and stem
cells would be isolated from an undamaged area of
the CNS, expanded in vitro, and grafted back to the
patient to repair the CNS. However, autologous
transplantation of adult-derived neural progenitor and
stem cells is not without limitations, like the potential
serious consequences of an invasive surgical
procedure and the possible permanent damage done
to harvest the patient cells. Neurogenesis also occurs
in the olfactory mucosa, the sense organ of smell that
produces new olfactory sensory neurons throughout
adulthood, including in human24-28. Neural progenitor
and stem cells have been isolated and characterized
from the adult olfactory mucosa of human, providing
a source of tissue for therapy29. Since olfactory
mucosa-derived neural progenitor and stem cells can
be isolated by simple biopsy from the nose, olfactory
mucosa-derived neural progenitor and stem cells
provide a promising candidate for autologous
transplantation in the nervous system17. Adult NSCs
also present several advantages over other cell types
for cellular therapy, like non-neuronal cell types, as
they permit the rewiring of the CNS, over ESCs that
have the risk to form tumours upon grafting, and
without the ethical and political hurdles associated
with SCNT and the use foetal-derived cells for
therapy. Altogether, these studies show that adult
NSCs provide an alternative source of tissue for
cellular therapy in the CNS, candidate for autologous
transplantation.
Adult stem cell plasticity: Adult stem cells are
multipotent: they generate cell types of tissues from
which they are derived. Several studies have reported
that adult-derived stem cells might not be restricted
to generate tissue specific cell types, but may have a
broader differentiation potential than previously
thought30,31. The ability to give rise to neuronal
lineages has been reported for stem cells derived the
hematopoietic system32, bone marrow33, skin34,
skeletal muscle35, adipose tissue36, as well as
umbilical cord37. The mechanisms underlying such
phenomenon remain to be fully determined. It is
hypothesized that the broader potential of adult stem
cells is controlled by the microenvironment in which
they reside. Stem cell niches are specialized
microenvironments that regulate stem cells activity.
Removing stem or progenitor cells from their original
environment that regulate their fate, may lead to the
expression of molecules that would confer the stem
cells a new fate, under a new environment38. The
evidences that adult-derived stem cells have a broader
potential suggest that alternative sources of adult
stem cells may be of use for cellular therapy,
particularly for the CNS, as NSCs could be derived
from other tissues, like the skin, permitting
autologous therapies in which a patient’s own cells
are removed from the skin, grown in a dish and
transplanted back into the patient. However, the
broader potential of adult stem cells remains the
source of debates and controversies30. Some reports
have raised concerns that the broader potential of
adult-derived stem cells could derive from
phenomenon like cell transformation,
transdifferentiation or fusion. All of which can affect
the use of adult stem cells for therapy. For example,
cell transformation may be associated with aberrant
cell growth, and the risk of tumour formation upon
grafting. So, a therapeutic effect could be associated
with potential risk for the patients. In all, the “true”
potential adult stem cells remains to be fully
characterized, before such strategy can be used for
therapy.
Conclusion
Although autologous transplantation represents
a model of choice for cellular therapy in the CNS,
yet only a few sources of tissues are candidates for
isogeneic transplantation, each with their respective
merits and limitations. Among them, adult NSCs
represent a promising model. There are several
questions that remain to be answered related to the
use of neural progenitor and stem cells for cellular
therapy, like the uncertain potential to establish the
right connections, to differentiate to specific neuronal
phenotypes, the optimal time for transplantation, the
optimal number of cells delivered, the site and route
of administration. Future studies will aim at
demonstrating the potential of adult NSCs for
therapy, and for autologous transplantation.
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